Biblio

Author [ Title(Desc)] Type Year
Filters: First Letter Of Title is V  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, et al. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. Br J Haematol. 2019.
Shah AMitesh, Pereira D, Poveda J, Wang TPeng. Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep. 2023;20:100380.
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, et al. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023.
Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, et al. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am J Hematol. 2021.
Zhao Y, Jiang S, Tang Y, Zhao L. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023.
Kwag D, Cho B-S, Bang S-Y, Lee JHyuk, Min G-J, Park S-S, Park S, Yoon J-H, Lee S-E, Eom K-S, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.
Juliusson G. Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia. Lancet Haematol. 2022;9(5):e317-e318.
Mekni S, Kanoun RYosra, Ladeb S, Belloumi D, Ben Abdeljelil N, Ben Othman T. Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report. Blood Res. 2023.
Szita VRéka, Wiedemann Á, Syoreni S, Tóth A, Ruff E, Gaál L, Masszi T, Varga G. [Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy]. Orv Hetil. 2023;164(23):894-899.
Gong X, Zhang Y, He X, Moloudizargari M, Yu T, Wang L, Liu W, Jin L, Xu H, Xu Y, et al. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Gong X, He X, Wang L, Yu T, Liu W, Xu H, Jin L, Li X, Zhang B, Tao Z, et al. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):17.
Kristensen DTuyet, Brøndum RFroberg, Ørskov ADue, Marcher CWerenberg, Schöllkopf C, Sørensen ALouise Tø, Severinsen MTang, Bøgsted M, Roug AStidsholt. Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy. Eur J Haematol. 2023.
Ravindra A, Acharya L, Loeffler B, Mott S, Sutamtewagul G, Dhakal P. Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia. Leuk Res. 2023;135:107407.
Murthy GSubramania, Atallah E. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346-350.
Nakada D. Venetolax with Azacitidine Drains Fuel from AML Stem Cells. Cell Stem Cell. 2019;24(1):7-8.
V JFHowick, Rezkalla JA, Tilbury T, Mankad SV, Bennett CE, Herrmann J, Barsness G, Ansell SM, Read MD. Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways. J Am Coll Cardiol. 2023.
Mirzaei S, Fekri HSamareh, Hashemi F, Hushmandi K, Mohamamdinejad R, Ashrafizadeh M, Zarrabi A, Garg M. Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacol Res. 2020:105327.
Szmit Z, Gorczyńska E, Mielcarek-Siedziuk M, Ussowicz M, Owoc-Lempach J, Kałwak K. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?. Adv Clin Exp Med. 2020.
Kreft A, Alverson C, Wagner-Drouet E-M, Ries I, Sommer C, Nat MSchindelde. Veno-occlusive disease of the lung after allogeneic haematopoietic stem-cell transplantation: An autopsy study. Pathol Res Pract. 2022;231:153799.
Dolapoglu A, Beketaev I. Venous thromboembolism in heart transplantation: Should we consider genetic predisposition?. J Heart Lung Transplant. 2014.
Chiu J, Lazo-Langner A. Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review. Thromb Res. 2023;226:141-149.
Zeidan AM, Wellman J, Forde PM, Bolaños-Meade J, Streiff MB. Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers. J Thromb Thrombolysis. 2013.
Hoskote S, Onigkeit J. Ventricular Bigeminy During Cryopreserved Autologous Hematopoietic Stem Cell Infusion. Chest. 2014;146(4_MeetingAbstracts):265A.
Lopez-Virgen V, Gonzalez-Morales O, Gonzalez-Perez O. The ventricular-subventricular, subgranular and subcallosal zones: three niches of neural stem cells in the postnatal brain. Exp Brain Res. 2023.

Pages